

Signe Leito

Saatja: mireille.kopf@edqm.eu
Saatmisaeg: neljapäev, 23. aprill 2026 12:58
Adressaat: Signe Leito
Teema: Addition of Lisdexamfetamine dimesylate to the Ph. Eur. work programme:
EDQM-2026-02041-mail

Järeltegevuse lipp: Järeltegevus
Olekulipp: Lipuga märgitud

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.

Please make sure to include in any reply our mail reference: EDQM-2026-02041-mail

European Pharmacopoeia Commission Secretariat

LETTER FOR THE ATTENTION OF NPAs

Copy: Presidium

Dear Colleagues,

Please find below the link to a survey being carried out concerning the proposed **addition** of Lisdexamfetamine dimesylate to the Ph. Eur. work programme.

In order to have access to the survey, please copy and paste this link into your Internet browser:
<https://survey.edqm.eu/index.php?r=survey/index&sid=553277&lang=en>

Deadline for replies: **23 May 2026**

With kind regards,

On behalf of Dr Jaume Sanz-Biset

Mireille Kopf

Secretarial Assistant

European Pharmacopoeia Department

EDQM - Council of Europe

Tel.: +33 (0)3 88 41 28 53 / Fax: +33 (0)3 88 41 27 71

<https://www.edqm.eu> / <https://store.edqm.eu>

Stay connected with the EDQM

Please make sure to include in any reply our mail reference: EDQM-2026-02041-mail